ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus…
Experts present lessons learned from past control programs and new approaches to eliminating diseases such as leprosy and malaria. The Novartis…
Designation highlights potential of BYM338 to address an unmet medical need in a serious disease If approved, BYM338 has the…
The International Biotechnology Leadership Camp (BioCamp) fosters idea exchange with leading scientists as well as entrepreneurship for young talents 60…
Lucentis® (ranibizumab) is the first licensed therapy to improve vision in patients with visual impairment due to choroidal neovascularization secondary to…
Recognition by the US Food and Drug Administration (FDA) that RLX030 has the potential to address a serious unmet medical…
Omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with refractory chronic spontaneous urticaria (CSU)[1] Omalizumab…